These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28879788)

  • 1. Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.
    Surenaud M; Lacabaratz C; Zurawski G; Lévy Y; Lelièvre JD
    Expert Rev Vaccines; 2017 Oct; 16(10):955-972. PubMed ID: 28879788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.
    Cobb A; Roberts LK; Palucka AK; Mead H; Montes M; Ranganathan R; Burkeholder S; Finholt JP; Blankenship D; King B; Sloan L; Harrod AC; Lévy Y; Banchereau J
    J Immunol Methods; 2011 Feb; 365(1-2):27-37. PubMed ID: 21093448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach.
    Gahery H; Choppin J; Bourgault I; Fischer E; Maillère B; Guillet JG
    Therapie; 2005; 60(3):243-8. PubMed ID: 16128266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic HIV Peptide Vaccine.
    Fomsgaard A
    Methods Mol Biol; 2015; 1348():351-7. PubMed ID: 26424286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.
    Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope-vaccine strategy against HIV-1: today and tomorrow.
    Liu Z; Xiao Y; Chen YH
    Immunobiology; 2003; 208(4):423-8. PubMed ID: 14748515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).
    Launay O; Surenaud M; Desaint C; Ben Hamouda N; Pialoux G; Bonnet B; Poizot-Martin I; Gonzales G; Cuzin L; Bourgault-Villada I; Lévy Y; Choppin J; Durier C
    Vaccine; 2013 Sep; 31(40):4406-15. PubMed ID: 23850610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
    Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.
    Wee EG; Ondondo B; Berglund P; Archer J; McMichael AJ; Baltimore D; Ter Meulen JH; Hanke T
    Mol Ther; 2017 Feb; 25(2):494-503. PubMed ID: 28153096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-based human immunodeficiency virus vaccine.
    Rinaldo CR
    J Intern Med; 2009 Jan; 265(1):138-58. PubMed ID: 19093966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals.
    Thiébaut R; Hejblum BP; Hocini H; Bonnabau H; Skinner J; Montes M; Lacabaratz C; Richert L; Palucka K; Banchereau J; Lévy Y
    Front Immunol; 2019; 10():874. PubMed ID: 31105698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of vaccine research and development: the human immunodeficiency virus (HIV).
    Girard MP; Osmanov SK; Kieny MP
    Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research.
    Fischer E; Rieux V; Guillet JG; Kazatchkine M
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):79-84. PubMed ID: 15867969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions.
    Ghunaim H; Kumar A; Torres J; Diaz-Mitoma F; Azizi A
    Vaccine; 2011 Aug; 29(35):5950-8. PubMed ID: 21718739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
    Salmon-Céron D; Durier C; Desaint C; Cuzin L; Surenaud M; Hamouda NB; Lelièvre JD; Bonnet B; Pialoux G; Poizot-Martin I; Aboulker JP; Lévy Y; Launay O;
    AIDS; 2010 Sep; 24(14):2211-23. PubMed ID: 20625264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.